Literature DB >> 23906493

The role of morning basal serum cortisol in assessment of hypothalamic pituitary-adrenal axis.

Churn-Ern Yip1, Samuel A Stewart, Fatima Imran, David B Clarke, Arati Mokashi, Stephanie M Kaiser, Syed A Imran.   

Abstract

PURPOSE: The use of morning basal serum cortisol levels as an alternative to dynamic testing for assessment of hypothalamic-pituitary-adrenal (HPA) axis has previously been reported. The purpose of this study was to determine the lower and upper cutoff values that would obviate subsequent HPA axis testing.
METHODS: A single-centre, retrospective study from a tertiary care endocrinology clinic was conducted, analyzing data from 106 adult individuals referred for HPA axis testing who had undergone a 0800-0900 morning basal serum cortisol test followed by a standard dose (250 μg) adrenocorticotropin (ACTH) stimulation test. The ability of morning basal serum cortisol values to predict post-ACTH 30 or 60 minute peak cortisol value of >500 or >550 nmol/L was investigated.
RESULTS: A morning basal cutoff of <128 nmol/L is sufficient for predicting a post-ACTH value<550 nmol/L, and morning basal cutoff levels of >243 nmol/L and >266 nmol/L predict peak post-ACTH values of >500 and >550 nmol/L respectively, obviating the need for dynamic testing. Regression analysis further demonstrated the log-linear relationship between morning basal and peak levels, while also finding a significant decrease in peak post-ACTH levels for patients diagnosed with secondary hypothyroidism (76 nmol/L lower, p=0.003) or secondary hypogonadism (61 nmol/L lower, p=0.02). These data suggest that the risk of cortisol deficiency is significantly higher in individuals with additional pituitary insufficiencies. The odds ratios for cortisol deficiency in patients with history of isolated secondary hypothyroidism was 3.41 (p=0.015), with isolated secondary hypogonadism was 4.77 (p=0.002) and with both was 7.45 (p=0.0002).
CONCLUSION: Morning basal serum cortisol levels show promise as an effective screening test for HPA insufficiency for most patients. Clinicians should consider the high probability of HPA insufficiency in patients with one or more pituitary insufficiencies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23906493     DOI: 10.25011/cim.v36i4.19955

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  11 in total

1.  Primary (autoimmune) hypophysitis: a single centre experience.

Authors:  Shruti Khare; Varsha S Jagtap; Sweta R Budyal; Rajeev Kasaliwal; Harshal R Kakade; Amol Bukan; Shilpa Sankhe; Anurag R Lila; Tushar Bandgar; Padmavathy S Menon; Nalini S Shah
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

2.  Gender differences in macroprolactinomas: a single centre experience.

Authors:  Shruti Khare; Anurag R Lila; Hiren Patt; Chaitanya Yerawar; Manjunath Goroshi; Tushar Bandgar; Nalini S Shah
Journal:  Endocr Connect       Date:  2015-12-18       Impact factor: 3.335

3.  The ICET-A Survey on Current Criteria Used by Clinicians for the Assessment of Central Adrenal Insufficiency in Thalassemia: Analysis of Results and Recommendations.

Authors:  Vincenzo De Sanctis; Ashraf T Soliman; Heba Elsedfy; Alice Albu; Soad Al Jaouni; Saif Al Yaarubi; Salvatore Anastasi; Duran Canatan; Massimo Di Maio; Salvatore Di Maio; Mohamed El Kholy; Mehran Karimi; Doaa Khater; Yurdanur Kilinc; Su Han Lum; Nicos Skordis; Praveen Sobti; Iva Stoeva; Ploutarchos Tzoulis; Yasser Wali; Christos Kattamis
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-07-01       Impact factor: 2.576

4.  Ambient air pollutants are associated with morning serum cortisol in overweight and obese Latino youth in Los Angeles.

Authors:  C M Toledo-Corral; T L Alderete; M M Herting; R Habre; A K Peterson; F Lurmann; M I Goran; M J Weigensberg; F D Gilliland
Journal:  Environ Health       Date:  2021-04-08       Impact factor: 7.123

5.  Improving the Interpretation of Afternoon Cortisol Levels and SSTs to Prevent Misdiagnosis of Adrenal Insufficiency.

Authors:  Vijay Ramadoss; Katharine Lazarus; Andrew Toby Prevost; Tricia Tan; Karim Meeran; Sirazum Choudhury
Journal:  J Endocr Soc       Date:  2021-09-04

6.  Pre-test Cortisol Levels in Predicting Short Synacthen Test Outcome: A Retrospective Analysis.

Authors:  Ravikumar Ravindran; Joanne L Carter; Asit Kumar; Florin Capatana; Ishrat N Khan; Mohamed A Adlan; Lakdasa D Premawardhana
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2022-05-06

7.  Prevalence of Opioid-Induced Adrenal Insufficiency in Patients Taking Chronic Opioids.

Authors:  Taoran Li; Julie L Cunningham; Wesley P Gilliam; Larissa Loukianova; Diane M Donegan; Irina Bancos
Journal:  J Clin Endocrinol Metab       Date:  2020-10-01       Impact factor: 5.958

8.  A comparative, population-based analysis of pituitary incidentalomas vs clinically manifesting sellar masses.

Authors:  Nadine M Vaninetti; David B Clarke; Deborah A Zwicker; Churn-Ern Yip; Barna Tugwell; Steve Doucette; Chris Theriault; Khaled Aldahmani; Syed Ali Imran
Journal:  Endocr Connect       Date:  2018-04-30       Impact factor: 3.335

9.  A randomized, phase IIa study to assess the systemic exposure of triamcinolone acetonide following injection of extended-release triamcinolone acetonide or traditional triamcinolone acetonide into both knees of patients with bilateral knee osteoarthritis.

Authors:  Alan Kivitz; Louis Kwong; Tammi Shlotzhauer; Joelle Lufkin; Amy Cinar; Scott Kelley
Journal:  Ther Adv Musculoskelet Dis       Date:  2019-10-16       Impact factor: 5.346

10.  Comparing the utility of 30- and 60-minute cortisol levels after the standard short synacthen test to determine adrenal insufficiency: A retrospective cross-sectional study.

Authors:  Muhammad Imran Butt; Nouf Alzuhayri; Lama Amer; Muhammad Riazuddin; Hadeel Aljamei; Muhammad Sohaib Khan; Mohammed Abufarhaneh; Eman Alrajhi; Anhar Alnassar; Reem Alahmed; Dina Mahmoud Ahmad Aljayar; Fayha Farraj Abothenain; Edward De Vol
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.